8-KLeadership ChangesExhibits & Filings

Alphabet Inc. 8-K Report, Executive Changes (Dec 9, 2019)

Filed December 9, 2019For Securities:GOOGLGOOGGOOGMGOOGN

Summary

Alphabet Inc. (GOOGL) announced on December 7, 2019, a significant addition to its Board of Directors with the appointment of Dr. Frances Arnold. Dr. Arnold, a Nobel laureate and distinguished professor at the California Institute of Technology, brings extensive scientific expertise, particularly in areas relevant to innovation and technology, which can be valuable for a company like Alphabet. Her appointment includes a substantial initial equity award and a standard compensation package for non-employee directors, indicating the board's recognition of her expertise and the value she is expected to bring. This move suggests Alphabet's continued focus on strengthening its governance and leveraging diverse, high-caliber talent to guide its strategic direction.

Key Highlights

  • 1Alphabet appointed Dr. Frances Arnold to its Board of Directors and Nominating and Corporate Governance Committee, effective December 7, 2019.
  • 2Dr. Arnold is a Nobel Prize winner in Chemistry and a distinguished professor at Caltech, bringing significant scientific and engineering expertise.
  • 3Her appointment is not based on any pre-existing arrangements or related-party transactions.
  • 4Dr. Arnold will receive an initial equity award valued at $1,000,000 in the form of Restricted Stock Units (GSUs) vesting over a period.
  • 5She will also receive standard annual compensation for non-employee directors, including a $350,000 GSU grant and a $75,000 cash retainer.
  • 6Dr. Arnold currently serves on the boards of Illumina, Inc. and Provivi, Inc., bringing valuable public and private company board experience.

Frequently Asked Questions

Frances Arnold is a Nobel laureate in Chemistry and a distinguished professor at the California Institute of Technology. Her appointment to Alphabet's Board of Directors on December 7, 2019, is intended to enhance the board's expertise, particularly in scientific and technological innovation, which is highly relevant to Alphabet's diverse business operations.

Dr. Arnold will receive an initial equity award of $1,000,000 in Alphabet's Restricted Stock Units (GSUs), which will vest over time. Following this, she is eligible for the company's standard annual compensation for non-employee directors, comprising a $350,000 GSU grant and a $75,000 cash retainer, with prorated amounts for the initial partial year.

Based on the filing, there are no arrangements or understandings that led to her selection, nor are there any reportable relationships or related-party transactions between Dr. Arnold and Alphabet Inc. She does serve on other boards, but this is disclosed as part of her professional background.

Dr. Arnold's background in chemical engineering, bioengineering, and biochemistry, particularly her work in protein engineering and directed evolution, offers deep scientific insight. This expertise can be valuable for Alphabet's strategic decisions, especially in areas like AI research, life sciences initiatives, and the development of new technologies.